CLINICAL APPLICATION & CRITERIA
CAR-T Cell Therapy in China
Cell therapy — most commonly chimeric antigen receptor T-cell (CAR-T) therapy — represents a revolution in cancer treatment: a patient’s own T cells are collected, genetically engineered in a specialized laboratory to recognize specific tumor antigens, expanded to large numbers, and infused back to seek and destroy cancer cells. As a living, one-time treatment, CAR-T can induce deep and durable remissions in patients with relapsed or refractory blood cancers who have exhausted all conventional options. The field is rapidly expanding beyond CD19 and BCMA in hematological malignancies to solid tumor targets, allogeneic ‘off-the-shelf’ products, CAR-NK cells, and in vivo manufacturing approaches.
- Potential for Deep Responses in Refractory Disease
- CD19 & BCMA Targets
- Emerging Solid-Tumor Applications
- Specialized CRS & ICANS Management
- Next-Generation Platforms
- Rapid Manufacturing Innovation
CLINICAL CANCER INDICATIONS
Key Cancers Treated with CAR-T Cell Therapy in China
China leads global clinical translation in autologous and allogeneic cellular therapies for hematologic malignancies and breakthrough solid tumor targets:
WHY CHOOSE US
Why Choose China Cancer Help for CAR-T Cell Therapy
A specialized clinical continuum connecting international patients directly with China’s National Clinical Research Centers for cell therapy.
As of 2026, China has approved more CAR-T products than any other country — nine NMPA-approved therapies versus six FDA-approved products in the United States — including the world’s first commercial solid-tumor CAR-T (satri-cel for Claudin18.2-positive gastric cancer, approved June 2026). China leads the world in registered CAR-T clinical trials, with over 500 active studies spanning hematological malignancies, solid tumors, and autoimmune diseases across 47+ qualified treatment centers.
Treatment costs are dramatically lower than in the US: an all-inclusive course in China ranges from approximately US$110,000–215,000, compared to US$500,000–900,000 in the United States — savings of 50–80%. Innovations include in vivo CAR-T (Huazhong University, published in The Lancet), same-day manufacturing (Xinqiao Hospital), and universal allogeneic platforms. High-volume centers such as Fudan Cancer Hospital, Ruijin Hospital, Peking Union, and Sun Yat-sen University have accumulated unparalleled real-world experience, with CRS mortality rates below 2%.
CASE EVALUATION PATHWAY
A Structured Pathway from Records to Care
A transparent, four-stage continuum connecting preliminary clinical evaluation to official hospital acceptance, specialized inpatient care, and ongoing continuity.
01. Submit Records Online
02. Pre-Screen & Doctor Match
03. Doctor Consultation
04. Travel to China & Care
PATIENT FAQS
Frequently Asked Questions
Key clinical, financial, and logistical insights for international CAR-T & Cellular Therapy patients considering care in China.
CAR-T CELL THERAPY PRE-ASSESSMENT
Request a Confidential Case Review for CAR-T Cell Therapy
Submit your contact details, confirmed diagnosis, and main question below. You do not need to upload any medical files at this stage. Our clinical coordinator will contact you directly within 24–48 hours to discuss potential CAR-T cell therapy pathways in China and assist you in gathering the specific medical records needed for expert hospital review.